16.08.2013 Views

Chemical and Biological Defense Program - Office of the Under ...

Chemical and Biological Defense Program - Office of the Under ...

Chemical and Biological Defense Program - Office of the Under ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

UNCLASSIFIED<br />

Exhibit P-5, Cost Analysis: PB 2014 <strong>Chemical</strong> <strong>and</strong> <strong>Biological</strong> <strong>Defense</strong> <strong>Program</strong> Date: April 2013<br />

Appropriation / Budget Activity / Budget Sub Activity:<br />

0300D: Procurement, <strong>Defense</strong>-Wide / BA 03: <strong>Chemical</strong>/<br />

<strong>Biological</strong> <strong>Defense</strong> / BSA 1: CBDP<br />

P-1 Line Item Nomenclature:<br />

MA0800 - JOINT BIO DEFENSE PROGRAM (MEDICAL)<br />

LI MA0800 - JOINT BIO DEFENSE PROGRAM (MEDICAL) UNCLASSIFIED<br />

<strong>Chemical</strong> <strong>and</strong> <strong>Biological</strong> <strong>Defense</strong> <strong>Program</strong> Page 9 <strong>of</strong> 17 P-1 Line #92<br />

Item Nomenclature (Item Number - Item<br />

Name, DODIC):<br />

JM8788 - NEXT GENERATION<br />

DIAGNOSTICS SYSTEM (NGDS)<br />

OCONUS laboratories operated by <strong>the</strong> Army, Navy <strong>and</strong> Air Force in coordination with <strong>the</strong> Armed Forces Health Surveillance Center. NGDS Increment 2 is intended to provide advanced diagnostics for<br />

biological pathogens <strong>and</strong> toxins, diagnostics for chemical <strong>and</strong> radiological exposures, <strong>and</strong> to provide capability to lower echelons <strong>of</strong> care.<br />

Justification: The FY14 NGDS program will procure 2 COTS components for NGDS Increment 1 Service Lab systems.<br />

RDT&E Code B Item: 0603884BP/Proj MB4; 0604384BP/Proj MB5; 0607384BP/Proj MB7<br />

MB4/NGDS: RDT&E FY11 <strong>and</strong> Prior - 1.581M; FY12 - 12.786M; FY14 - 19.322M; FY15 - 7.500M; FY16 - 13.358M; FY17 - 14.000M; FY18 - 12.000M<br />

MB5/NGDS: RDT&E ; FY13 - 9.827M; FY14 - 8.636M; FY15 - 6.318M; FY16 - 6.420M; FY17 - 6.420M; FY18 - 6.420M<br />

MB7/NGDS: RDT&E ; FY14 - 0.499M; FY15 - 13.414M; FY16 - 14.551M; FY17 - 9.816M; FY18 - 3.277M<br />

DEVELOPMENT/TEST STATUS AND MAJOR MILESTONES<br />

NGDS - CRP - Development <strong>and</strong> Implementation <strong>of</strong> Quality Initiatives, Validation <strong>Program</strong>, <strong>and</strong> Systems Engineering (Sep 2006 to Mar 2015)<br />

NGDS - CRP - ISO certification (Jun 2007 to Sep 2014)<br />

NGDS - Increment 1 MS A: Feb 2012<br />

NGDS - Conduct market research, CP planning <strong>and</strong> Source Selection (Feb 2012 to Dec 2012)<br />

NGDS - Increment 1 Competitive Prototyping Phase (Dec 2012 to Jun 2013)<br />

NGDS - Increment 1 Development <strong>and</strong> FDA approval <strong>of</strong> Anthrax/VHF assays (Jun 2013 to Mar 2015)<br />

NGDS - Increment 1 Tularemia <strong>and</strong> Plague IVD assay development (Mar 2015 to Dec 2015)<br />

NGDS - Increment 1 MS C: Jun 2015<br />

NGDS - Increment 2 MS A: Sep 2014<br />

NGDS - Increment 2 MS C: Sep 2018<br />

55

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!